Table 1.
Baseline patient characteristics.
| Characteristic | All (n = 606) | PPI group (n = 54)a | Non-PPI group (n = 552)a | ||
|---|---|---|---|---|---|
| Capecitabine monotherapy (n = 29) | CapeOX (n = 25) | Capecitabine monotherapy (n = 420) | CapeOX (n = 132) | ||
| Age, median (IQR), y | 63 (55–70) | 63 (58–70) | 61 (55–66) | 64 (57–71) | 60 (51–67) |
| Sex | |||||
| Male | 328 (54.1) | 11 (37.9) | 12 (48.0) | 226 (53.8) | 79 (59.8) |
| Female | 278 (45.9) | 18 (62.1) | 13 (52.0) | 194 (46.2) | 53 (40.2) |
| Primary sitea | |||||
| Right-sided colon | 171 (28.2) | 7 (24.1)b | 3 (12.0) | 123 (29.3)c | 38 (28.8) |
| Left-sided colon | 215 (35.5) | 8 (27.6) | 7 (28.0) | 161 (38.3)d | 39 (29.5)e |
| Rectum | 220 (36.3) | 14 (48.3)f | 15 (60.0) | 136 (32.4)g | 55 (41.7) |
| Stage | |||||
| II | 73 (12.0) | 6 (20.7) | 1 (4.0) | 60 (14.3) | 6 (4.5) |
| IIIA | 106 (17.5) | 6 (20.7) | 4 (16.0) | 81 (19.3) | 15 (11.4) |
| IIIB | 341 (56.3) | 14 (48.3) | 12 (48.0) | 237 (56.4) | 78 (59.1) |
| IIIC | 86 (14.2) | 3 (10.3) | 8 (32.0) | 42 (10.0) | 33 (25.0) |
| Co-administered PPIs | |||||
| Lansoprazole | 30 (55.6) | 13 (44.8) | 17 (68.0) | ||
| Esomeprazole | 10 (18.5) | 6 (20.7) | 4 (16.0) | ||
| Rabeprazole | 10 (18.5) | 7 (24.1) | 3 (12.0) | ||
| Omeprazole | 4 (7.4) | 3 (10.3) | 1 (4.0) | ||
aPercentages may not add up to 100 because of rounding.
bOne patient had concurrent sigmoid colon cancer.
cFive patients had concurrent gastric cancer (n = 2), both cecum and transverse colon cancers (n = 1) (because cecum cancer was more malignant than transverse colon cancer, the patient was registered as having cecum cancer), and sigmoid colon cancer (n = 2).
dEight patients had concurrent head and neck cancer (n = 1), gastric cancer (n = 3), transverse colon cancer (n = 1), and rectal cancer (n = 3).
eThree patients had concurrent gastric cancer (n = 2), and prostate cancer (n = 1).
fOne patient had concurrent transverse colon cancer.
gOne patient had concurrent transverse colon cancer.
Abbreviations: CapeOX, capecitabine and oxaliplatin; IQR, interquartile range; PPI, proton pump inhibitor.